Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$0.33 - $1.39 $73,167 - $308,189
221,719 New
221,719 $281,000
Q2 2022

Aug 15, 2022

SELL
$0.86 - $2.06 $130,529 - $312,664
-151,779 Reduced 93.32%
10,867 $12,000
Q1 2022

May 16, 2022

SELL
$1.83 - $3.02 $384,144 - $633,943
-209,915 Reduced 56.34%
162,646 $333,000
Q4 2021

Feb 14, 2022

BUY
$2.88 - $4.3 $678,804 - $1.01 Million
235,696 Added 172.21%
372,561 $1.07 Million
Q3 2021

Nov 15, 2021

BUY
$3.72 - $5.35 $346,648 - $498,539
93,185 Added 213.34%
136,865 $580,000
Q1 2021

May 17, 2021

SELL
$3.33 - $8.76 $312,836 - $822,958
-93,945 Reduced 68.26%
43,680 $203,000
Q4 2020

Feb 16, 2021

BUY
$3.27 - $4.64 $114,675 - $162,720
35,069 Added 34.19%
137,625 $454,000
Q3 2020

Nov 16, 2020

BUY
$3.23 - $4.3 $154,507 - $205,690
47,835 Added 87.42%
102,556 $339,000
Q2 2020

Aug 14, 2020

SELL
$3.31 - $6.54 $718,134 - $1.42 Million
-216,959 Reduced 79.86%
54,721 $184,000
Q1 2020

May 15, 2020

BUY
$2.9 - $6.16 $76,522 - $162,543
26,387 Added 10.76%
271,680 $1.04 Million
Q4 2019

Feb 14, 2020

BUY
$5.61 - $8.57 $1.05 Million - $1.61 Million
187,876 Added 327.21%
245,293 $1.48 Million
Q3 2019

Nov 14, 2019

BUY
$7.56 - $15.44 $349,158 - $713,096
46,185 Added 411.19%
57,417 $434,000
Q2 2019

Aug 16, 2019

SELL
$5.4 - $15.5 $472,311 - $1.36 Million
-87,465 Reduced 88.62%
11,232 $152,000
Q1 2019

May 15, 2019

SELL
$3.6 - $6.22 $403,189 - $696,621
-111,997 Reduced 53.16%
98,697 $535,000
Q4 2018

Feb 14, 2019

SELL
$2.89 - $7.91 $342,661 - $937,872
-118,568 Reduced 36.01%
210,694 $625,000
Q3 2018

Nov 14, 2018

BUY
$5.59 - $10.45 $1.17 Million - $2.18 Million
208,871 Added 173.49%
329,262 $2.69 Million
Q2 2018

Aug 14, 2018

SELL
$7.98 - $12.39 $400,133 - $621,259
-50,142 Reduced 29.4%
120,391 $1.17 Million
Q4 2017

Feb 14, 2018

BUY
$8.69 - $14.59 $1.48 Million - $2.49 Million
170,533
170,533 $2.14 Million

Others Institutions Holding ZYNE

About Zynerba Pharmaceuticals, Inc.


  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.